NEW YORK Boehringer Ingelheim has done a major service to the industry with the release of this report. Closing the gap on patient compliance and adherence remains not only the best opportunity for retail pharmacy to grow the business at a time of waning big blockbuster drug introductions and continued pressure from generic competition, but also represents the best opportunity for this industry to “show what it’s got,” as the entire nation turn its attention to health reform.
